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Live  attenuated  vaccines  have  been  proposed  as a strategy  to induce  protective  immunity  against  infec-
tious  diseases.  Recent  data  have  demonstrated  that  nasopharyngeal  colonisation  with  Streptococcus
pneumoniae  induces  protective  immunity  against  subsequent  invasive  infection,  suggesting  nasal  vac-
cination  with live  attenuated  bacteria  could  be  a  preventative  strategy.  However  the  bacterial  factors
affecting  the strength  of  this adaptive  immune  response  remain  unclear.  In  a direct  comparison  with
the parent  wild-type  strain,  we  found  that  colonisation  with  bacteria  lacking  either  capsule  or  surface
lipoproteins  led to  signiﬁcantly  diminished  protection.  Immunity  after  colonisation  was  not  dependent  on
serum IgG  to capsular  antigens.  Colonisation  density  and duration  was  reduced  for all  the non-protective
strains,  suggesting  that protective  immunity  maybe  related  to the  extent  of nasopharyngeal  bacterial
exposure.  To  investigate  this  hypothesis,  we  utilised  an  auxotrophic  bacterial  pab  strain  where  dura-uxotroph
ipoprotein
tion of  colonisation  could  be controlled  by  supply  and  removal  of  para-amino-benzoic  acid  (PABA)  to
mouse  drinking  water.  Supporting  colonisation  with  the  pab  strain  for 5  days  with  PABA  led  to  a  faster
serum  antibody  response  compared  to colonisation  for  less  than  48  h.  This  enhanced  immunogenicity
was  associated  with  a trend  towards  protection.  The  data  presented  here  aid our  understanding  of  why
only certain  live  attenuated  strains  are  able  to function  as  effective  vaccines,  and  may  be  valuable  in
informing  the  constituents  of future  live  attenuated  vaccines.. Introduction
Streptococcus pneumoniae is a global pathogen responsible
or the deaths of over one million individuals annually, mostly
ue to pneumonia [1]. Initial exposure to the bacteria is in the
asopharynx, where they establish colonisation. Usually, episodes
f nasopharyngeal colonisation are essentially asymptomatic, and
o not lead to disease [2].  In certain cases however, when the range
f innate and adaptive immune mechanisms is insufﬁcient to pre-
ent disease, aspiration of bacteria can lead to pneumonia. This is
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most common at the extremes of life and amongst immunocom-
promised individuals. Vaccines have been directed to this speciﬁc
need.
At present, licensed vaccines elicit protection through induction
of opsonophagocytic antibodies against capsular polysaccharide
antigens [3].  Once conjugated to carrier proteins, a process nec-
essary to induce protection in infants, these vaccines can lead to
reduction in carriage as well as disease. These conjugate vaccines
are very effective at reducing disease caused by the S. pneumoniae
serotypes included in the vaccine directly in the vaccinees and indi-
rectly in the wider community. However, serotypes not included in
the vaccine can replace the eliminated strains within the nasophar-
ynx, leading to replacement disease [4].  Despite recent increases
in the number of serotypes included in vaccine formulations, it is
likely that alternative strategies will be required in the long-term
to protect against S. pneumoniae [3].
Live vaccines can lead to both humoral and cellular immune
responses. Inclusion of a large number of antigens and natural bac-
terial adjuvants can lead to strong immunity in the absence of an
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xogenous adjuvant. Nasopharyngeal colonisation with live bacte-
ial strains represents one such route of mucosal immunisation.
Using murine models, we [5] and others [6,7] have studied the
echanisms by which prior colonisation can protect against sub-
equent lethal invasive pneumonia. Antibody responses induced
hrough colonisation with a live wild-type (WT) strain are both
ecessary and sufﬁcient to protect against invasive disease [5].
uch protection does not necessarily require antibodies to capsular
olysaccharide, since experimental colonisation with unencapsu-
ated strains is also protective [6].  Unencapsulated mutants are an
ttractive option for live attenuated vaccines due to their lack of
irulence [6,8], but no direct comparison of the immunogenicity
nd protective efﬁcacy of colonisation with isogenic strains with
nd without capsule has been reported.
Bacterial lipoproteins are an important class of pathogen-
ssociated molecular pattern (PAMP), capable of adjuvanting
mmune responses [9] by acting as ligands for TLR2 [10], and are
ommon targets for adaptive immune responses [11,12]. Dele-
ion of lgt,  which encodes the protein diacylglyceryl transferase
equired to anchor lipoproteins to the cell membrane, results in
n S. pneumoniae strain with greatly reduced quantities of lipopro-
eins on the bacterial surface (Chimalapati, under review) [13]. This
lgt strain is still able to colonise the mouse nasopharynx, albeit
ith both reduced density and shorter duration than its parent WT
train. Its ability to induce protective immunity is not known.
The gene pabB encodes para-amino benzoic acid (PABA) syn-
hase, required for the folate biosynthetic pathway. Deletion of this
ene leads to an auxotrophic mutant where growth is dependent
pon exogenous supply of PABA [11]. It is unlikely to affect capsule
xpression since phagocytosis of the pab strain in vitro is simi-
ar to that of its parent strain [11]. The pab mutation does not
igniﬁcantly effect lipoprotein expression, since such strains can
obustly induce anti-lipoprotein antibodies when inoculated via
he intraperitoneal route [11]. This mutation results in an inabil-
ty to replicate in vivo, and was previously reported to lead to rapid
learance of TIGR4pab from the nasopharynx within 2 days. This
utant was also avirulent unless the animal’s drinking water was
upplemented with PABA [11]. Again, its ability to induce protec-
ion through colonisation is not known.
In this study, we address the speciﬁc contribution of the pres-
nce of capsule and surface lipoproteins on colonisation-induced
mmunogenicity and protection against subsequent lethal pneu-
onia. We ﬁnd that absence of either capsule or lipoproteins leads
o failure to protect, reﬂecting reduced immunogenicity. Using
ontrolled colonisation with an auxotrophic mutant, we  ﬁnd that
uration and density of colonisation directly impacts on the speed
f the immune response, with potential impact on subsequent pro-
ection.
. Methods
.1. Ethics statement
Experiments were approved by the UCL Biological Services
thical Committee and the UK Home Ofﬁce (Project Licence
PL70/6510). Experiments were performed according to UK
ational guidelines for animal use and care, under UK Home Ofﬁce
icence and in accordance with EU Directive 2010/63/EU.
.2. Bacterial strains and culture conditionsWild-type (WT) S. pneumoniae strain D39 (serotype 2) and its
nencapsulated derivative containing a deletion of cpsD (D39-D)
14] were a kind gift from James Paton, University of Adelaide. Dele-
ional mutant strain D39pab lacking PAB synthetase or lgt were0 (2012) 4453– 4459
generated by overlap extension PCR as described [11] (Chimalap-
ati, under review). Bacteria were cultured on Columbia agar with
5% horse blood or in Todd–Hewitt broth with 0.5% yeast extract
in 5% CO2. Inocula for challenge experiments were prepared from
mid-log phase cultures and stored at −70 ◦C as single use aliquots.
2.3. Colonisation and infection models
CD1 outbred mice were obtained from Charles River UK Ltd.
Mice were colonised by instillation of 107 cfu S. pneumonia in 10 l
PBS into the nares under light halothane anaesthesia as previously
[5,15]. In certain experiments, mice received a second colonising
dose 2 weeks after the ﬁrst dose. Control mice received 10 l PBS
alone. To obtain nasal washes the exposed trachea was ﬂushed cau-
dally with 200 l PBS and the ﬂuid exiting the nares collected. For
the pneumonia challenge, 107 cfu S. pneumonia D39 in 50 l PBS
was instilled into the nares under deep general halothane anaes-
thesia 28 days after the ﬁnal colonising dose [5,15,16]. Animals
were culled by exsanguination from the femoral artery under pen-
tobarbital anaesthesia. Broncheo-alveolar lavage ﬂuid (BALF) was
collected by cannulating the exposed trachea and washing the air-
ways three times serially with 1 ml  sterile PBS. Lungs were collected
aseptically into ice-cold PBS, minced and homogenised with sterile
PBS as previously [5,17].  For survival experiments, animals were
monitored and culled when exhibiting previously deﬁned features
of terminal disease [16].
2.4. Whole cell ELISA
Antibodies speciﬁc to antigens in different S. pneumoniae strains
were measured by whole cell ELISA using established methods
as previously described [8].  Brieﬂy, S. pneumoniae were grown to
late log-phase, washed and resuspended in PBS to OD580 1.0. 96-
well plates were coated with this bacterial suspension, refrigerated
overnight, then blocked with PBS 1% BSA prior to use. Sera were
diluted in PBS 1% BSA before addition and binding to bacterial anti-
gens detected with anti-mouse secondary antibodies conjugated to
alkaline phosphatase (Sigma).
2.5. Capsule ELISA
To measure capsule-speciﬁc antibodies, plates were coated with
type 2 puriﬁed capsular polysaccharide (CPS) at 10 g/ml (LGC Pro-
mochem). To increase assay speciﬁcity, sera were pre-incubated
with cell wall polysaccharide (Statens Serum Institut) and type
22F capsular polysaccharide (LGC Promochem) as previously [11].
Development of ELISAs proceeded as for whole cell ELISAs.
2.6. Competitive inhibition ELISA
To determine the relative contribution of CPS binding towards
the total binding observed in whole cell ELISA, sera were pre-
incubated in PBS/1% BSA with increasing concentrations of soluble
type 2 CPS up to 100 g/ml for 30 min  at RT, prior to assay in whole
cell ELISA as above.
2.7. Luminex anti-pneumococcal protein antibody assay
Antibody responses to multiple protein antigens were mea-
sured using a multiplex ﬂow cytometry Luminex assay based on
S. pneumoniae proteins conjugated to xMAP beads, as previously
[11]. Recombinant TIGR4-, D39-, or serotype 23 strain-derived pro-
teins were conjugated to xMAP beads (Luminex) [18]. Combined
beads (3000 per antigen) were incubated with 10% or 1% serum
in PBS–1% bovine serum albumin and then with goat anti-mouse
IgG-phycoerythrin (Jackson ImmunoResearch). IgG binding was
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Fig. 1. Protective effect of prior colonisation on subsequent S. pneumoniae pneu-
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Fig. 2. Serum antibody response to colonisation. Serum IgG (A), IgA (B) and IgMonia. Kaplan–Meier survival curves of mice challenged with 107 cfu of D39 i.n., 28
ays  after colonisation with either one or two (×2) doses of 107 cfu of D39, D39-D,
39lgt,  D39pab or PBS alone (n = 18–20). *P < 0.05, ***P < 0.001.
ubsequently assessed using a Bioplex instrument (Bio-Rad Labs)
nd Bio-Plex Manager software. Data are presented as log10 MFIs
f IgG binding to each bead type, after subtraction of the results for
lank beads. There was no binding to proteins using serum from
ontrol mice.
.8. Statistics
Bacterial loads were compared at speciﬁc time-points by
ann–Whitney U-test. Antibody levels were compared between
roups of mice by two-tailed Student’s t-test. Survival of challenged
ice was compared by the log rank test. P values <0.05 were con-
idered signiﬁcant.
. Results
.1. Protection against lethal pneumonia challenge
To assess the protection induced through colonisation with
ild-type D39, unencapsulated D39-D,  lipoprotein-deﬁcient
39lgt or auxotrophic D39pab,  groups of 20 outbred CD1 mice
ere colonised with 107 cfu of these strains. A further group
eceived 2 colonising doses of 107 cfu D39, 2 weeks apart. A con-
rol group received PBS in place of bacterial colonisation. All mice
ere challenged nasally at the same time, 28 days following ﬁnal
olonisation, with 107 cfu WT  D39 (Fig. 1). In addition, serum was
lso collected from 10 mice per group the day prior to challenge. In
his invasive pneumonia model, challenge led to septicaemia with
eath of the majority of control mice (15% survival), with a median
urvival of 2.29 days. Mice previously colonised with D39 WT  were
rotected against challenge with a survival of 40% (group median
urvival time 4.04 days, P = 0.003). Amongst mice that received 2
olonising doses of D39, survival was improved at 55% (P = 0.001).
owever, mice colonised with the mutant strains were not signif-
cantly protected, with survival rates of 30% (median survival 2.02
ays) in mice colonised with D39-D,  25% (median survival 2.0
ays) in mice colonised with D39lgt and 25% (median survival
.87 days) in mice colonised with D39pab.
.2. Immunogenicity following colonisation
The lack of protection afforded with D39-D,  D39lgt or
39pab in this model suggested that colonisation with these
trains was insufﬁciently immunogenic to protect against inva-
ive pneumonia. To test this, antibody was measured in individual
era from colonised and control mice. Antibodies to total bacterial
ntigens were measured by whole cell ELISA (Fig. 2). 70% of mice(C)  responses to colonisation with either one or two (×2) doses of D39, D39-D,
D39lgt  or PBS alone, measured using whole cell ELISA. Dots indicate responses of
individual mice, bars represent mean for the group. *P < 0.05, ***P < 0.001.
colonised with D39 developed an IgG ELISA titre response to D39
greater than the level observed in control mice which had been
sham colonised with PBS. This increased to 100% in mice receiv-
ing two doses. Only in mice colonised with the wild-type strain
were IgG levels signiﬁcantly higher than those observed in controls.
In groups receiving unencapsulated D39-D, lipoprotein-deﬁcient
D39lgt or auxotrophic D39pab,  less than 50% of mice developed
anti-D39 IgG titres greater than that seen in controls. There was
no evidence for signiﬁcant anti-D39 IgA or IgM responses by day
28 post-colonisation with any of the strains. The degree of protec-
tion against invasive pneumonia challenge afforded by the different
strains correlated strongly with the levels of serum anti-D39 IgG
(r2 = 0.94, P < 0.001) (Fig. 3). These responses are in accordance with
the immunogenicity of D39 colonisation in inbred CBA/Ca mice [5],
where protection is known to be mediated by serum IgG.
Colonisation with an unencapsulated mutant of a type 6A strain
of S. pneumoniae can induce protection against challenge with the
encapsulated parent WT  strain [6]. We  were therefore surprised
that D39-D was  poorly immunogenic in our model. We  initially
hypothesised that protection induced through colonisation with
the wild-type strain was mediated through anti-capsular antibody.
If so, lack of this critical antigen would explain the limited immuno-
genicity of the unencapsulated strain. Serum anti-type 2 capsular
polysaccharide IgG was measured by ELISA (Fig. 4A). Whilst nearly
all mice colonised with WT D39 developed an IgG response as
measured in whole cell ELISA (Fig. 2A), only an occasional mouse
developed a capsule-speciﬁc IgG response (Fig. 4A). Anti-CPS IgG
made a negligible contribution to total IgG binding as assayed by
whole cell ELISA since pre-incubation of sera with excess puri-
ﬁed capsular polysaccharide antigen did not inhibit IgG binding
in sera from mice colonised with WT  D39 (Fig. 4B). To further
conﬁrm that colonisation with WT  D39 induced antibody against
4456 J.M. Cohen et al. / Vaccine 3
Fig. 3. Correlation of immunogenicity with protection following nasopharyngeal
colonisation. Coloured dots and bars represent immunogenicity as anti-D39WT IgG
geomean titre (GMT) of the group (±95% CI) versus percentage survival (±95% CI) of
the  group against day 28 D39WT pneumonia challenge. Dotted line shows correla-
tion  between immunogenicity and protection by linear regression.
Fig. 4. Serum anti-capsular IgG response to colonisation. (A) Serum anti-type 2 cap-
sular polysaccharide IgG response to colonisation with either one or two (×2) doses
of  D39, D39-D,  D39lgt,  D39pab or PBS alone, measured by ELISA. Dots indicate
responses of individual mice, bars represent mean for the group. (B) Competitive
i
i
r
n
1
o
p
m
a
F
anhibition of binding of serum IgG to total D39 antigens in whole cell ELISA using
ncreasing concentrations of soluble type 2 capsular polysaccharide. Bars represent
elative mean ± SD of binding of sera from individual mice (n = 4).
on-capsular antigens, levels of IgG that bound to pneumolysin and
5 surface-accessible protein antigens was measured in the serum
f 3 randomly selected WT  D39 colonised mice (Fig. 5). Antibody to
neumococcal surface protein A (PspA) and the lipoprotein pneu-
ococcal surface adhesin A (PsaA) were detected in 3 out of 3 mice,
nd IgG to the lipoprotein putative proteinase maturation protein
ig. 5. Serum anti-protein IgG responses to colonisation. IgG binding of sera of three indiv
ssay.  Dotted line represents limit of detection.0 (2012) 4453– 4459
(PpmA) in 2 of 3 mice. Thus, colonisation with the encapsulated
WT strain induced antibody to bacterial proteins including lipopro-
teins, but not to capsular polysaccharide. Colonisation with either
D39-D or D39lgt was less immunogenic, correlating with their
lack of protection.
3.3. Density and duration of colonisation
Since neither D39-D and D39pab lacked the potentially pro-
tective antigens present in WT  D39, we generated the alternative
hypothesis that lack of protection reﬂected insufﬁcient antigen
exposure during the colonisation process. To explore this, we  com-
pared the density and duration of nasopharyngeal colonisation
with these strains (Fig. 6). D39 colonisation persisted until at least
day 10 following inoculation, but no bacteria were recovered by day
17. The ability of D39-D to colonise was  impaired. Compared to
WT,  there were approximately 1-log fewer unencapsulated D39-
D recovered at both day 1 and day 2 post-inoculation, with
colonisation cleared in nearly all mice by day 5. As seen previ-
ously with TIGR4pab [11], D39pab bacteria were rapidly cleared
within 48 h of attempted colonisation. We  also found that D39lgt
has a shorter duration of colonisation (cleared by day 10) and lower
colonisation density (approximately 1–1.5 log10 fewer) compared
to WT  D39 (data from Chimalapati et al., under review) (Fig. 6).
Thus, the immunogenicity of the protective WT  strain may  reﬂect
contributions by both capsule and surface lipoproteins to main-
taining the degree of bacterial nasopharyngeal exposure required
to induce protective immunity.
3.4. Effect of duration of colonisation on immune response
To assess whether the duration of bacterial colonisation could
be controlled using PABA supplementation of this mutant, we
attempted to colonise mice with D39pab in the presence of PABA
supplementation. PABA supplementation was  commenced the day
prior to colonisation, and abruptly withdrawn after 5 days (Fig. 7A).
In the presence of PABA, numbers of D39pab were maintained in
the nasopharynx at a level similar to that seen with WT  D39. When
withdrawn on day 5, bacterial numbers rapidly fell, and were no
longer detectable after 48 h, by day 7 post-colonisation.
To investigate the impact of controlled colonisation on immuno-
genicity and protection, further groups of mice were colonised with
D39pab in the presence or absence of PABA for 5 days. Serum anti-
D39 IgG level was  assessed at 14 and 28 days, prior to pneumonia
challenge with WT D39. By day 14 post-colonisation, mice receiv-
ing 5 days of PABA supplementation had approximately 10-fold
greater median serum IgG against D39 than those not receiving
PABA (Fig. 7B). By day 28, levels were not signiﬁcantly different
between the groups, indicating more rapid development of an
antibody response when growth of the auxotrophic bacteria was
supported at this level. In mice colonised with D39pab alone,
there was  no evidence of protection (median survival time 3.00
idual WT D39 colonised mice to S. pneumoniae proteins measured by Luminex bead
J.M. Cohen et al. / Vaccine 30 (2012) 4453– 4459 4457
Fig. 6. Timecourse of colonisation with S. pneumoniae D39 strains. Bacterial cfu recovered from nasal washes of CD1 mice on days 1, 2, 5, 10 and 17 following intranasal
inoculation in 10 l of PBS containing 107 cfu D39 S. pneumoniae (closed squares) or D39-D (open squares), D39pab (closed circles) or D39lgt (open circles). Median
and  interquartile range of groups of 4–9 mice at each timepoint are shown, along with the precise number in the group. The dotted line is the limit of detection.
Fig. 7. Effect of para-aminobenzoic acid (PABA) supplementation on immunogenicity and protection. (A) Bacterial cfu recovered from nasal washes on days 1, 2, 5 and 7
following intranasal inoculation with 107 cfu D39pab in the presence of PABA supplementation. PABA was withdrawn on day 5. Dots represent results for individual mice,
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lards  represent group median. The dotted line is the limit of detection. (B) Serum an
ith  (black circles) or without (white circles) 5 days of PABA supplementation. Bar
ays  after colonisation with D39pab with or without 5 days of PABA supplementa
ays, overall survival 30%) compared to controls (median time
.87 days, 20% survival) (Fig. 7C). In mice where colonisation was
upported with PABA, there was a trend towards longer survival
ompared with controls (median survival time 6.90 days, overall
urvival 35%, P = 0.09). Thus, the enhanced immune kinetics sug-
ested that the degree of nasopharyngeal bacterial exposure was
irectly impacting on subsequent immunogenicity, and could make
 contribution towards protection.
. DiscussionLive attenuated vaccines must possess both antigens and
djuvants which persist in sufﬁcient quantity in an appropriate
ocation for enough time to induce a protective response. We IgG level measured by whole cell ELISA at 0, 14 and 28 days following colonisation
ate group mean. *P < 0.05. (C) Survival following challenge with 107 cfu D39 i.n. 28
or with PBS alone (n = 15).
have investigated how multiple factors may contribute towards
the immunogenicity of a colonising bacterial strain and determine
whether the colonisation event is sufﬁcient to induce protection.
We have previously shown prior colonisation protects against inva-
sive D39 pneumonia by preventing septicaemia with no protection
at the mucosal level and is dependent on serum antibody [5].  Hence,
systemic IgG rather than local immunological responses to coloni-
sation are likely to be the important protective response for this
model of S. pneumoniae infection, and this was  supported by the
close correlation between the serum IgG response and protective
efﬁcacy for the different strains studied here.Compared to its WT parent strain, D39pab was poorly
immunogenic following colonisation. Supplementation with PABA
for 5 days restored the ability of D39pab to colonise, and enhanced
the speed of anti-D39 IgG seroconversion. The majority of mice with
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ABA supplementation had high titres of anti-D39 IgG, whereas in
ice without PABA titres were much more variable. This was asso-
iated with a strong trend towards protection. These data support
he hypothesis that for a given strain of S. pneumoniae, the dura-
ion of colonisation is important in generating protective immunity.
hether the ‘area under the curve’ (reﬂecting total antigen present
ver time i.e. abundance as well as duration of colonisation) is more
mportant than duration alone is not clear. Unencapsulated and
spA/ply mutants have been reported which also have shorter dura-
ion of colonisation at lower densities than the parent WT  strain
6]. These were however still able to induce protective immune
esponses in C57BL/6 mice [6].  This may  reﬂect a greater propen-
ity to induce stronger protection in this inbred strain, which may
xplain the greater protection seen following WT  D39 colonisation
f CBA/Ca mice [5] than the CD1 mice reported here. It may  be more
hallenging to achieve protection in outbred mice due to multiple
enetic differences between individual mice including the MHC.
rotection has been shown for a pneumolysin-deﬁcient D39 strain
n outbred MF1  mice [7],  but colonisation with this strain persisted
or 7–14 days and was not dissimilar to the duration of WT  D39 in
D1 mice reported here.
Colonisation with the WT  D39 strain induced high titres of anti-
acterial serum IgG, yet no detectable anti-capsular IgG. This was
lso found following D39 colonisation of CBA/Ca mice [5] and MF1
ice [7].  We  have also found that colonisation of CD1 mice with
he TIGR4 strain did not induce anti-capsular serum IgG (unpub-
ished data). Together, these data suggest that, in mice, a single
asopharyngeal colonisation event is not sufﬁcient to induce a
erum anti-CPS IgG response, at least for serotype 2 and 4 capsules.
olonisation has a variable effect on induction of serum anti-CPS
gG responses in humans. In a longitudinal family study, serotypes
V, 14, 18C, 19F and 23F induced anti-CPS responses, but serotype
B did not [19]. Following carriage in a childhood study, responses
ere detected to serotypes 11A and 14, but not to serotypes 6B,
9F and 23F [20]. Furthermore, experimental human colonisation
id not induce an anti-capsular serum IgG response [21]. Immuno-
enicity of capsule following colonisation events is likely to reﬂect
 complex interaction of bacterial strain, CPS type, host genetics, as
ell as the current and previous constituents of the nasopharyn-
eal microbiome. Ongoing longitudinal studies correlating detailed
arriage history with serological data may  elucidate this further.
The absence of anti-capsular serum IgG did not prevent coloni-
ation with WT  D39 from inducing protection against lethal
hallenge, albeit at a weaker level in these CD1 mice compared
o results with in-bred strains [5].  Immunity to non-capsular
ntigens induced through colonisation is known to be sufﬁcient
o protect [6].  Our data imply that whilst capsular antigens are
ot dominant during colonisation, the presence of capsule does
ot impede the development of anti-protein mediated protective
mmunity. On the contrary, the increased level and duration of
olonisation with encapsulated compared to unencapsulated bac-
eria resulted in an increased antibody response to protein antigens
nd improved protection to subsequent challenge. Thus, for the
trains tested here, the potentially stronger immunogenicity due to
reater exposure of surface proteins in the unencapsulated strain
s offset by shorter less-dense colonisation, rendering the strain
on-protective. In this regard, it would be interesting to directly
ompare the immunogenicity and protective efﬁcacy of colonisa-
ion with unencapsulated strains that are known to protect [6] with
hose of their WT  parent strains. It is possible that WT  strains in
eneral would emerge as more immunogenic than unencapsulated
sogenic mutants.The reduced immunogenicity of the lgt mutant is likely to
eﬂect a combination of factors. Most important of these may  be
he reduced colonisation density and duration. In addition, coloni-
ation with WT  D39 induced serum IgG to only 3 of 16 proteins0 (2012) 4453– 4459
antigens tested and two of these three were lipoproteins. Thus if
the antibodies binding these antigens makes a critical contribu-
tion to protection of the WT  strain, the absence of the antigens
in D39lgt would signiﬁcantly impair its ability to protect. TLR2
signalling is important in the induction of Th17-cell responses
through S. pneumoniae colonisation. Thus, mice lacking TLR2 have
delayed clearance of S. pneumoniae [22,23]. Reduced TLR2 sig-
nalling from D39lgt may  therefore impair the induction of the
Th17 response and could reduce the immunogenicity of the lgt
strain. However, data from TLR2 deﬁcient mice suggest that this
pathway may  be redundant in the induction of robust serum IgG
responses to colonisation [24], perhaps due to other compensating
pathogen recognition pathways. Similarly, TLR4 [25] and inﬂam-
masome [26,27] activation by pneumolysin may also be redundant
in this regard, since pneumolysin-deﬁciency bacteria are also capa-
ble of inducing protection [7],  perhaps due to intact TLR2 signalling.
Prior colonisation protects against re-colonisation through
Th17-mediated rapid neutrophil recruitment [23]. Hence, although
we did not measure the bacterial load in the nasopharynx after the
second dose, we  would anticipate it is cleared more rapidly than the
original inoculum. The ability of repeated doses of nasopharyngeal
inoculation to induce stronger immune responses has been pre-
viously reported and can be protective even with mutant strains
[6,28]. Hence once sufﬁcient bacterial exposure has occurred to
induce a primary immune response, further exposure with a second
inoculation probably acts as an immunological booster even with-
out prolonged duration of dense colonisation. It is thus possible that
administering repeated doses of any of the non-protective mutant
strains reported in this work may  enhance immunity sufﬁcient to
cause protection.
The data presented here directly comparing the several non-
protective mutant bacterial strains with their protective parent WT
strain aid our understanding of why certain live attenuated strains
are able to function as effective vaccines. Duration and/or density of
colonisation appear important in determining this, but comparison
to other data suggests thresholds clearly vary between different
bacterial strains and hosts. For live attenuated strains containing
other disabling mutations, sustaining colonisation by inclusion of
capsule may  be a strategy to enhance the immunogenicity of the
non-capsular antigens present in the strain and induce protection
against invasive disease.
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